Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

Author： Tan Sean P.   Chouaid C.   Hettler D.   Baud M.   Hejblum G.   Tilleul P.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.6, 2009-06, pp. : 1455-1460

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 29, Iss. 4, 2006-03 ,pp. : 171-178

Karger

Access to resources Recommend Favorite

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 599-604

Karger

Access to resources Recommend Favorite

Treosulfan as Reinduction Chemotherapy in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 320-322

Karger

Access to resources Recommend Favorite

Combination of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer

By  

Oncology, Vol. 59, Iss. 2, 2000-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite